Methods Ethical approval was granted by Coventry and Warwickshire research ethics committee (09/H1211/38). We collected 5 mls of urine from 31 HCC cases from January to June 2019. Male to female ratio was 5:1 and mean age was 72 years. Urine samples were left to freeze within 2 hours to −80°C. Analysis of the samples completed at the end of recruitment. Prior to analysis samples were left to thaw in a water bath at 50°C for 1 h. Urine was then placed into a Falcon conical centrifuge tube 50-mL with a modified cap with two slots to allow two solid phase microextraction tabs to be inserted to absorb gases from the head space of the samples. These tabs were analysed using an array of eight metal oxide gas sensors. Responses from the gas sensors to the urinary vapours were captured over a period of 180 seconds, then digitized and stored by computer software. The receiver operating characteristics (ROC) curves were calculated using established algorithm that was applied to different classes of data generated from an artificial radial basis function network (RBFN).

Results The sensitivity of AFP alone in our study for HCC detection was 54.8% (raised AFP >10 kU/L in only 17 cases). When comparing urinary VOCs to AFP, they showed good discrimination in diagnosis of HCC. The sensitivity for detection of HCC with normal AFP was 68% (ROC Curve Area was 0.68, SE 0.06, 95% CI 0.54 to 0.81 and P <0.005). The VOCs sensitivity in detection of HCC cases with raised AFP was 83% (ROC Curve Area was 0.83, SE 0.05, 95% CI 0.73 to 0.93 and P<0.0001) as demonstrated in the figure 1 below.

Conclusion Urinary VOCs could have a potential role in screening and surveillance of HCC. It is an attractive tool because it is non-invasive and has a low cost. Further validation from studies with larger sample size is required.

Introduction Hepatocellular carcinoma (HCC) is a frequent cause of death. HCC development is associated with liver inflammation, protein changes and fibrotic deposition. We investigated the low molecular weight urinary proteome in HCC to further advance our understanding of the disease.

Methods We recruited 51 cases from university hospital Coventry/UK and Hannover medical school/Germany from January 2013 to June 2019. Ethical approval was granted from the appropriate bodies and consent was obtained from all participants. There were 20 HCC cases on background of liver cirrhosis (mean age of 60 years, 3 females and 17 males) and 31 controls (mean age 59 years, 11 females and 20 males). The controls included 9 non-alcoholic fatty liver disease, 13 non-alcoholic steato hepatitis and 9 healthy controls. 5 mls of urine was collected from each participant and frozen to -80°C. Analysis of the urine samples was completed by applying capillary electrophoresis (CE) coupled to mass spectrometry (MS). CE-MS is a hybrid technology using capillary electrophoresis (CE) for separation and mass spectrometry (MS) for mass detection enabling multidimensional analyte detection in complex biofluids. Raw CE-MS data processing and normalization procedures for inter-sample analysis were completed using computer software. Peptide sequences were resolved by tandem-MS and proteases potentially involved in HCC progression were matched to the N- and C terminal sequence motifs of the CE-MS identified peptide markers for HCC by the online software tool Proteasix.

Results In silico protease prediction revealed that there were the following eight urinary proteases involved in the generation of the HCC-specific urinary peptide marker: Stromelysin-1, Cathepsin K, Cathepsin E, Cathepsin D, Cathepsin B, Cathepsin A, Cathepsin L, Cathepsin S. A preliminary analysis of the data demonstrated the potential of urinary protease biomarkers as markers for HCC progression.

Abstract P174 Table 1

<table>
<thead>
<tr>
<th>Gene name</th>
<th>MEPE1A</th>
<th>MMP3</th>
<th>CTSE</th>
<th>MMP13</th>
<th>GZMA</th>
<th>KLK6</th>
<th>CTSD</th>
<th>CTSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full name</td>
<td>Meprin A subunit alpha</td>
<td>Stromelysin-1</td>
<td>Cathepsin B</td>
<td>Collagenase 3</td>
<td>Granzyme A</td>
<td>Kallikrein-6</td>
<td>Cathepsin D</td>
<td>Cathepsin E</td>
</tr>
<tr>
<td>Avg. Cases</td>
<td>196.2</td>
<td>632.99</td>
<td>347.63</td>
<td>729.36</td>
<td>197.81</td>
<td>166.4</td>
<td>32.9</td>
<td>34.41</td>
</tr>
<tr>
<td>SD. Cases</td>
<td>93.1</td>
<td>317.56</td>
<td>173.63</td>
<td>402.76</td>
<td>165.3</td>
<td>79.87</td>
<td>33.44</td>
<td>31.99</td>
</tr>
<tr>
<td>Avg. Controls</td>
<td>386.8</td>
<td>393.63</td>
<td>643.77</td>
<td>495.03</td>
<td>330.32</td>
<td>67.98</td>
<td>17.35</td>
<td>22.56</td>
</tr>
<tr>
<td>SD. Controls</td>
<td>231.1</td>
<td>331.29</td>
<td>399.1</td>
<td>539.78</td>
<td>188.06</td>
<td>88.51</td>
<td>31.21</td>
<td>41.25</td>
</tr>
<tr>
<td>Fold change (Cases/Controls)</td>
<td>0.53</td>
<td>1.6</td>
<td>0.63</td>
<td>1.47</td>
<td>0.59</td>
<td>2.47</td>
<td>1.89</td>
<td>1.52</td>
</tr>
<tr>
<td>Regulation in HCC</td>
<td>Down</td>
<td>Up</td>
<td>Down</td>
<td>Up</td>
<td>Down</td>
<td>Up</td>
<td>Up</td>
<td>Up</td>
</tr>
<tr>
<td>Mann-Whitney test</td>
<td>P = 0.003</td>
<td>P = 0.006</td>
<td>P = 0.003</td>
<td>P = 0.01</td>
<td>P = 0.01</td>
<td>P &lt; 0.0001</td>
<td>P = 0.015</td>
<td>P = 0.031</td>
</tr>
</tbody>
</table>
1 (MMP3), Collagenase 3 (MMP13), Kallikrein-6 (KLK6), Cathepsin D (CTSD) and Cathepsin E (CTSE) had increased activity whilst Meprin A subunit alpha (MEP1A), Cathepsin B (CTSB) and Granzyme A (GZMA) had reduced activity in HCC compared to controls.

Conclusions Urinary CE-MS analysis identified eight proteases specific to HCC. These proteases could be associated with the development of HCC. Recent cancer research revealed that most of the proteases associated with cancer are involved in the degradation of the extracellular matrix and are also involved in the growth and spreading of cancer in the body.

**Abstract P175**

**URINARY ANALYSIS OF HEPATOCELLULAR CARCINOMA PATIENTS USING SOLID PHASE MICROEXTRACTION**

1,2Ayman Bannaga*, 3Frank Kvasnik, 3Krishna Persaud, 1,2Ramesh Arasaradnam. 1University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK; 2Warwick Medical School, University of Warwick, Coventry, UK; 3School of Chemical Engineering and Analytical Science, University of Manchester, Coventry, UK

10.1136/gutjnl-2020-bsgcampus.250

**Introduction** Solid phase microextraction (SPME) is an analytical method for preconcentration of volatile organic compounds (VOCs) commonly used in analysis of biological samples. We applied SPME to study the urinary signatures of VOCs in hepatocellular carcinoma (HCC) patients.

**Methods** Ethical approval was granted by Coventry and Warwickshire research ethics committee (09/H1211/38). We conducted a prospective recruitment between January to June 2019. Male to female ratio was 5:1 and mean age was 72 years (range 42 to 94). HCC cases were diagnosed as per EASL recommendations for 2018. Controls included patients that were suspected of cancer but had negative investigations. We collected 5 mls of urine from 31 HCC cases and 18 controls. The urine samples were left to freeze within 2 hours to − 80°C. Analysis of these samples was then completed at the end of study recruitment. Prior to analysis samples were left to thaw in a water bath at 50°C for 1 h. Urine was then placed into a Falcon conical centrifuge tube 50-mL with a modified cap with two slots to allow two solid phase microextraction tabs to be inserted to absorb gases from the head space of the samples. The tabs were then analysed using an array of eight metal oxide gas sensors. Responses from the gas sensors (1 to 8) to the urinary vapours were captured over a period of 180 seconds. The responses were digitized and stored by a computer software. The method of principal components analysis (PCA) was then employed to visualize these data.

**Results** Data from the eight gas sensor responses were then demonstrated on a PCA plot, which made no assumptions about separation between classes. This visually showed that responses from the urinary VOCs of HCC patients were clearly differentiated from controls as shown in the plot below. This gives the impression that HCC has a potential urinary specific chemical signature. Urinary VOCs signature could potentially be used in the diagnosis of HCC.

**Conclusions** Application of SPME urinary VOCs analysis in HCC patients has future potential as a diagnostic method. This will require further validation from other interested research groups.

**Abstract P176**

**TSPAN6: A NOVEL PLAYER IN THE MICROENVIRONMENT OF PRIMARY LIVER CANCERS**

1OO Bolimowska*, 1DA Patten, 2S Shetty, 2B Berditchevski, 1JM O’Rourke, 1OC Cain, 1AL Wilkinson. 1Centre for Liver and Gastrointestinal Research, University of Birmingham, UK; 2CRUK Institute for Cancer Studies, University of Birmingham, UK

10.1136/gutjnl-2020-bsgcampus.251

**Introduction** Tetraspanins, a large family of membrane proteins, have been implicated in the regulation of the tumour microenvironment of a number of cancers. TSPAN6 has previously been shown to modulate the immune microenvironment in breast cancers via indirect interactions with tumour-infiltrating B cells; however, TSPAN6 has not been studied within the context of primary liver cancers, nor the human liver in general.

**Methods** TSPAN6 mRNA expression was quantified in normal, chronically diseased and primary liver cancer tissues. The distribution and cellular localisation of TSPAN6 protein expression was explored utilising immunohistochemistry and multi-colour immunofluorescence. In addition, hepatocellular carcinoma (HCC) tumour samples were histologically scored on intensity and proportion of positivity for TSPAN6 and Kaplan-Meier curves were generated for patients with negative/low expression vs. positive TSPAN6 tumour expression.

**Results** Transcriptional expression of TSPAN6 was comparable between normal and chronically diseased liver tissues, but was increased in primary liver cancer tissues, compared to matched distal tissues. TSPAN6 was strongly expressed in biliary epithelial cells, and to a lesser degree in hepatocytes within normal tissues and showed increased expression in the diseased state. In chronically diseased tissues, a strong association with the fibrotic septa was observed and we show that TSPAN6 strongly co-localised with cytokeratin 7, a marker of intermediate cells in the ductular reaction. TSPAN6-expressing cells were also in close association with aggregates of CD20+ B cells within diseased tissues. Primary liver cancer tumours showed variable expression of TSPAN6 and preliminary analysis in HCC tumours suggested a correlation between positive tumour TSPAN6 expression and better overall patient survival, over a 5 year period.

**Conclusions** In this study, we have described, for the first time, the expression of TSPAN6 in human liver tissues. Chronically diseased liver tissues showed increased protein expression of TSPAN6 compared to normal tissues, and its expression was largely associated with the fibrotic septa and...